Sanofi Pasteur MSD Limited

Mallards Reach, Bridge Avenue, Maidenhead, Berkshire, SL6 1QP
Telephone: +44 (0)1628 785 291
Fax: +44 (0)1628 671 722
Medical Information Direct Line: +44 (0)1628 587 693
Medical Information e-mail: medinfo@spmsd.com
Medical Information Fax: +44 (0)1628 635 072
Patient Information Leaflet last updated on the eMC: 24/09/2009
PIL GARDASIL

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 24/09/2009 and displayed until Current
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 04/08/2009 and displayed until 24/09/2009
Reasons for adding or updating:
  • Change to side-effects
  • Change to drug interactions
  • Change to dosage and administration
Updated on 30/06/2009 and displayed until 04/08/2009
Reasons for adding or updating:
  • Change to side-effects
Updated on 18/06/2009 and displayed until 30/06/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 17/06/2009 and displayed until 18/06/2009
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
Updated on 12/03/2009 and displayed until 17/06/2009
Reasons for adding or updating:
  • Change to side-effects
Updated on 05/12/2008 and displayed until 12/03/2009
Reasons for adding or updating:
  • Improved Electronic Presentation
  • Change to date of revision
  • Change to side-effects
  • Change to MA holder contact details
Updated on 11/11/2008 and displayed until 05/12/2008
Reasons for adding or updating:
  • Change to warnings or special precautions for use
  • Change to side-effects
Updated on 15/09/2008 and displayed until 11/11/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to warnings or special precautions for use
  • Changes to therapeutic indications
Updated on 08/08/2008 and displayed until 15/09/2008
Reasons for adding or updating:
  • Change to date of revision
  • Change to side-effects
  • Changes to therapeutic indications
Updated on 03/07/2008 and displayed until 08/08/2008
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 21/05/2008 and displayed until 03/07/2008
Reasons for adding or updating:
  • Change to MA holder contact details
Updated on 26/02/2008 and displayed until 21/05/2008
Reasons for adding or updating:
  • Change to Further Information section
Updated on 15/08/2007 and displayed until 26/02/2008
Reasons for adding or updating:
  • Change to side-effects
  • Change to date of revision
Updated on 12/07/2007 and displayed until 15/08/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 20/02/2007 and displayed until 12/07/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 17/10/2006 and displayed until 20/02/2007
Reasons for adding or updating:
  • New PIL for new product

Active Ingredients/Generics

 
   human papillomavirus vaccine


© 2009 Datapharm Communications Ltd

Go to www.medicines.org.uk